Cargando…
Integrative Radiogenomics Approach for Risk Assessment of Postoperative and Adjuvant Chemotherapy Benefits for Gastric Cancer Patients
Gastric cancer (GC) is a typical heterogeneous malignant tumor, whose insensitivity to chemotherapy is a common cause of tumor recurrence and metastasis. There is no doubt regarding the effectiveness of adjuvant chemotherapy (ACT) for GC, but the population for whom it is indicated and the selection...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8602567/ https://www.ncbi.nlm.nih.gov/pubmed/34804945 http://dx.doi.org/10.3389/fonc.2021.755271 |
_version_ | 1784601602996305920 |
---|---|
author | Jin, Yin Xu, Yilun Li, Yanyan Chen, Renpin Cai, Weiyang |
author_facet | Jin, Yin Xu, Yilun Li, Yanyan Chen, Renpin Cai, Weiyang |
author_sort | Jin, Yin |
collection | PubMed |
description | Gastric cancer (GC) is a typical heterogeneous malignant tumor, whose insensitivity to chemotherapy is a common cause of tumor recurrence and metastasis. There is no doubt regarding the effectiveness of adjuvant chemotherapy (ACT) for GC, but the population for whom it is indicated and the selection of specific options remain the focus of present research. The conventional pathological TNM prediction focuses on cancer cells to predict prognosis, while they do not provide sufficient prediction. Enhanced computed tomography (CT) scanning is a validated tool that assesses the involvement of careful identification of the tumor, lymph node involvement, and metastatic spread. Using the radiomics approach, we selected the least absolute shrinkage and selection operator (LASSO) Cox regression model to build a radiomics signature for predicting the overall survival (OS) and disease-free survival (DFS) of patients with complete postoperative gastric cancer and further identifying candidate benefits from ACT. The radiomics trait-associated genes captured clinically relevant molecular pathways and potential chemotherapeutic drug metabolism mechanisms. Our results of precise surrogates using radiogenomics can lead to additional benefit from adjuvant chemotherapy and then survival prediction in postoperative GC patients. |
format | Online Article Text |
id | pubmed-8602567 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-86025672021-11-20 Integrative Radiogenomics Approach for Risk Assessment of Postoperative and Adjuvant Chemotherapy Benefits for Gastric Cancer Patients Jin, Yin Xu, Yilun Li, Yanyan Chen, Renpin Cai, Weiyang Front Oncol Oncology Gastric cancer (GC) is a typical heterogeneous malignant tumor, whose insensitivity to chemotherapy is a common cause of tumor recurrence and metastasis. There is no doubt regarding the effectiveness of adjuvant chemotherapy (ACT) for GC, but the population for whom it is indicated and the selection of specific options remain the focus of present research. The conventional pathological TNM prediction focuses on cancer cells to predict prognosis, while they do not provide sufficient prediction. Enhanced computed tomography (CT) scanning is a validated tool that assesses the involvement of careful identification of the tumor, lymph node involvement, and metastatic spread. Using the radiomics approach, we selected the least absolute shrinkage and selection operator (LASSO) Cox regression model to build a radiomics signature for predicting the overall survival (OS) and disease-free survival (DFS) of patients with complete postoperative gastric cancer and further identifying candidate benefits from ACT. The radiomics trait-associated genes captured clinically relevant molecular pathways and potential chemotherapeutic drug metabolism mechanisms. Our results of precise surrogates using radiogenomics can lead to additional benefit from adjuvant chemotherapy and then survival prediction in postoperative GC patients. Frontiers Media S.A. 2021-11-05 /pmc/articles/PMC8602567/ /pubmed/34804945 http://dx.doi.org/10.3389/fonc.2021.755271 Text en Copyright © 2021 Jin, Xu, Li, Chen and Cai https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Jin, Yin Xu, Yilun Li, Yanyan Chen, Renpin Cai, Weiyang Integrative Radiogenomics Approach for Risk Assessment of Postoperative and Adjuvant Chemotherapy Benefits for Gastric Cancer Patients |
title | Integrative Radiogenomics Approach for Risk Assessment of Postoperative and Adjuvant Chemotherapy Benefits for Gastric Cancer Patients |
title_full | Integrative Radiogenomics Approach for Risk Assessment of Postoperative and Adjuvant Chemotherapy Benefits for Gastric Cancer Patients |
title_fullStr | Integrative Radiogenomics Approach for Risk Assessment of Postoperative and Adjuvant Chemotherapy Benefits for Gastric Cancer Patients |
title_full_unstemmed | Integrative Radiogenomics Approach for Risk Assessment of Postoperative and Adjuvant Chemotherapy Benefits for Gastric Cancer Patients |
title_short | Integrative Radiogenomics Approach for Risk Assessment of Postoperative and Adjuvant Chemotherapy Benefits for Gastric Cancer Patients |
title_sort | integrative radiogenomics approach for risk assessment of postoperative and adjuvant chemotherapy benefits for gastric cancer patients |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8602567/ https://www.ncbi.nlm.nih.gov/pubmed/34804945 http://dx.doi.org/10.3389/fonc.2021.755271 |
work_keys_str_mv | AT jinyin integrativeradiogenomicsapproachforriskassessmentofpostoperativeandadjuvantchemotherapybenefitsforgastriccancerpatients AT xuyilun integrativeradiogenomicsapproachforriskassessmentofpostoperativeandadjuvantchemotherapybenefitsforgastriccancerpatients AT liyanyan integrativeradiogenomicsapproachforriskassessmentofpostoperativeandadjuvantchemotherapybenefitsforgastriccancerpatients AT chenrenpin integrativeradiogenomicsapproachforriskassessmentofpostoperativeandadjuvantchemotherapybenefitsforgastriccancerpatients AT caiweiyang integrativeradiogenomicsapproachforriskassessmentofpostoperativeandadjuvantchemotherapybenefitsforgastriccancerpatients |